On Monday 19th of January, the Cellestial Team attended BioSeed by OBN to re-connect with the London life sciences community and share why our approach to astrocytic network restoration matters in Parkinson’s.
✦ For brain cells, we are looking to reduce the burden of abnormal protein aggregates and inflammation via a novel mechanism
✦ For people with Parkinson’s, we want to offer an approach that prevents a range of motor and non-motor symptoms from getting worse
✦ For early investors, we seek to demonstrate opportunities for suitable exit scenarios
It is not easy to cover in five minutes, so please feel free to reach out to us for a further discussion.